Vilon

Vilon is a very short synthetic peptide made of just two amino acids, lysine and glutamic acid, giving the sequence Lys-Glu ^[1][5]. It belongs to a group of so-called peptide bioregulators, sometimes called ultrashort peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson ^[1]. Within this system Vilon is classed as a thymus-associated peptide, meaning it was designed to reproduce the regulatory activity attributed to extracts of the thymus gland, the organ central to immune development ^[1].

The peptide bioregulator concept grew out of decades of Russian work on complex peptide preparations extracted from animal tissues, from which shorter, defined peptides such as Vilon were later synthesized to carry tissue-specific effects ^[1]. Vilon was created as a dipeptide counterpart to the thymus preparation, and it has mainly been studied within this Russian research tradition ^[1][2].

Reported research has focused on immune modulation and aging ^[1][2]. Laboratory and animal studies describe Vilon as an immunomodulator, and it has been examined as an adjunct in areas such as the care of elderly cancer patients, where it was explored for possible effects on immunity, recovery and quality of life ^[3]. It has also been tested in experimental models, for example alongside surgery in a rat model of endometriosis and in studies of tumor development in mice ^[4][5]. Researchers propose that peptides of this type act by influencing gene expression ^[2].

Vilon and related peptide bioregulators are used and marketed chiefly within Russia and some neighboring countries, where they have been sold as bioregulator preparations; they are not approved as medicines by agencies such as the U.S. Food and Drug Administration or the European Medicines Agency ^[1]. Much of the published evidence consists of small studies and reviews from a limited number of laboratories, frequently published in Russian, so the findings are considered preliminary and have not been widely reproduced by independent groups. It is generally encountered as a research peptide rather than an established therapy.

Vilon is a synthetic dipeptide bioregulator from the Khavinson peptide research, promoted for immune and longevity effects, with essentially no rigorous, independently validated human safety data and no approval as a medicine. The evidence is largely limited to Russian studies, and its long-term safety is unknown. Its effects in people with immune or other chronic conditions are unstudied.

Vilon is a synthetic dipeptide (Lys-Glu) developed within the Russian program of short peptide bioregulators led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The program grew out of earlier work on peptide extracts of the thymus, and Vilon was designed as a simplified, defined-sequence peptide intended to reproduce immunomodulatory and geroprotective effects attributed to those extracts.

Beginning around the late 1990s and into the 2000s, the originating laboratories published a series of experimental reports describing effects on immune parameters, gene expression, and lifespan in laboratory animals. It is important to note that essentially all of this research originates from a small group of affiliated Russian investigators, and the findings have not been broadly replicated or validated by independent groups outside that tradition. Vilon is not an approved medicine in the United States, the European Union, or other Western jurisdictions, and its status remains that of an experimental research peptide.

Vilon occupies an intriguing niche in the world of longevity and immune-support peptides, drawing interest from enthusiasts attracted to the Russian peptide-bioregulator tradition and its unusually simple two-amino-acid design. Advocates point to the originating laboratories' reports of immunomodulatory and geroprotective activity, including experiments describing extended lifespan and reduced tumor incidence in aging mice.

The concept behind it, that very short peptides might influence gene expression in specific tissues, is a genuinely novel and thought-provoking hypothesis. At the same time, an honest appraisal must stress that the supporting evidence comes almost entirely from a single research lineage and has not been independently confirmed, and that human clinical data are sparse. Vilon is therefore best understood as a compelling but still unproven experimental peptide rather than an established therapy.